HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immun
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immun
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immun
HUTCHMED (China) Ltd. 其他疾病 小分子化药 单克隆抗体 一眼洞穿机构专注的疾病领域 项与 和黄医药(中国)有限公司 相关的临床试验 NCT05690035 /Withdrawn PD-1 Antibody (Tislelizumab) Combined With VEGFR 1/2/3 Inhibitor (Fruquintinib) for ARID1A-mutated Metastatic pMMR/MSS Colorectal Cancer: an ...
Latest HUTCHMED (China) Ltd (13:HKG) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Global biopharma with strong in-house R&D platform. Founded in 2000, HUTCHMED (HCM) is a global biopharma with strong in-house R&D platform in developing targeted therapies in oncology and immunology. HCM has assembled a highly differentiated pipeline of 13+ assets under clinical development/ IND-...
和黄医药(HUTCHMED)是一家上市公司,成立于2000年,总部在中国香港,HKG代码为13。 (文中的所有图片均已设置链接,可直接点击图片跳转到新药情报库免费查看对应图片最新数据详细信息) 和黄医药一直致力于新药研发。当前在研药物数量为15个,覆盖了新药研发流程的不同阶段。详细来说,处于临床2期和批准上市阶段的药物数量最...
HutchMed的肺癌治疗取得突破性地位 和记医疗(中国)有限公司(HK:0013)已发布更新。和奇医疗(中国)有限公司宣布其ORPATHYS®和TAG的联合疗法.
Latest HUTCHMED (China) Ltd (HCM:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
The latest news, analysis and opinion on HUTCHMED (China) Ltd.. In-depth analysis, industry insights and expert opinion